NOVOSEVEN Infusion

Eptacog Alfa
2.4mg (120 KIU)
Novo Nordisk A/S
Pack size 2.4mg Vial (Powder) + Solvent Vial + Kit
Dispensing mode POM
Source DENMARK
AgentCITY MEDICAL STORE
Retail Price 8199.00 AED

Indications

NOVOSEVEN Infusion is used for: Hemophilia, bleeding episodes

Adult Dose

Intravenous Bleeding episodes in patients with haemophilia Adult: As activated eptacog alfa: Initially, 90 mcg/kg given via IV bolus over 2-5 min. Additional dose may be given as needed to achieve or maintain haemostasis, initially 2-3 hrly. May adjust dose or dosing interval according to response. May continue therapy for up to 3 wk or more in cases of serious bleeding episodes. Bleeding episodes due to surgery or invasive procedures in patients with factor VII deficiency Adult: As activated eptacog alfa: 15-30 mcg/kg 4-6 hrly via IV bolus over 2-5 min until haemostasis is achieved.

Child Dose

Renal Dose

Administration

Contra Indications

Hypersensitivity to the active substance, the excipients, or to mouse, hamster or bovine protein.

Precautions

Patient w/ conditions associated w/ circulating tissue factor (e.g. advanced atherosclerosis, crush injury or septicaemia) due to risk of precipitating thrombosis or disseminated intravascular coagulation. Pregnancy and lactation.

Pregnancy-Lactation

Interactions

Risk of potential DI w/ coagulation factor conc unknown. Avoid simultaneous use of prothrombin complex conc, activated or not. Not recommended to combine rFVIIa & rFXIII.

Adverse Effects

Side effects of Eptacog Alfa : Nausea, vomiting, skin reactions, fever, headache and changes in BP. Rarely, anaphylaxis.

Mechanism of Action

The mechanism of action includes the binding of factor VIIa to exposed tissue factor. This complex activates factor IX into factor IXa and factor X into factor Xa, leading to the initial conversion of small amounts of prothrombin into thrombin. Thrombin leads to the activation of platelets and factors V and VIII at the site of injury and to the formation of the haemostatic plug by converting fibrinogen into fibrin.

Note

NOVOSEVEN 2.4mg (120 KIU) Infusion manufactured by Novo Nordisk A/S. Its generic name is Eptacog Alfa. NOVOSEVEN is availble in United Arab Emirates. Farmaco UAE drug index information on NOVOSEVEN Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Eptacog Alfa :